Antibody based therapeutics for autoimmune hemolytic anemia

References

• Berentsen S, Barcellini W. Autoimmune Hemolytic Anemias. N Engl J Med. 2021 Oct 7;385(15):1407–1419. doi: 10.1056/NEJMra2033982.
   PubMed Web of Science ®Google Scholar
• Barcellini W, Fattizzo B. Strategies to overcome the diagnostic challenges of autoimmune hemolytic anemias. Expert Rev Hematol. 2023 Jul;16(7):515–524. doi: 10.1080/17474086.2023.2216930
   PubMed Web of Science ®Google Scholar
• Barcellini W, Fattizzo B. How I treat warm autoimmune hemolytic anemia. Blood. 2021 Mar 11;137(10):1283–1294. Erratum in: Blood. 2023 Jan 26;141(4):438-439. doi: 10.1182/blood.2019003808
   PubMed Web of Science ®Google Scholar
• Barcellini W, Fattizzo B, Zaninoni A, et al. Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patients. Blood. 2014 Nov 6;124(19):2930–2936. doi: 10.1182/blood-2014-06-583021.
   PubMed Web of Science ®Google Scholar
• Barcellini W, Zaninoni A, Fattizzo B, et al. Predictors of refractoriness to therapy and healthcare resource utilization in 378 patients with primary autoimmune hemolytic anemia from eight Italian reference centers. Am J Hematol. 2018 Sep;93(9):E243–E246. doi: 10.1002/ajh.25212
   PubMed Web of Science ®Google Scholar
• Wang Z, Bo L, Xu Y, et al. Features of serum complement C3 and C4 levels in autoimmune hemolytic anemia patients. Int J Lab Hematol. 2021;43(5):1154–1158. doi: 10.1111/ijlh.13469
   PubMed Web of Science ®Google Scholar
• Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia. 2022 Jul;36(7):1703–1719. doi: 10.1038/s41375-022-01613-1
   PubMed Web of Science ®Google Scholar
• Jäger U, Barcellini W, Broome CM, et al. Diagnosis and treatment of autoimmune hemolytic anemia in adults: recommendations from the first international consensus meeting. Blood Rev. May 2020;41:100648. doi: 10.1016/j.blre.2019.100648.
   PubMed Web of Science ®Google Scholar
• Petz LD, Garratty G. Drug-induced haemolytic anemia. Clin Haematol. 1975 Feb;4(1):181–197. doi: 10.1016/S0308-2261(21)00631-7
   PubMedGoogle Scholar
• Reynaud Q, Durieu I, Dutertre M, et al. Efficacy and safety of rituximab in auto-immune hemolytic anemia: a meta-analysis of 21 studies. Autoimmun Rev. 2015 Apr;14(4):304–313. doi: 10.1016/j.autrev.2014.11.014
   PubMed Web of Science ®Google Scholar
• Ho G, Brunson A, Keegan THM, et al. Splenectomy and the incidence of venous thromboembolism and sepsis in patients with autoimmune hemolytic anemia. Blood Cells Mol Dis. 2020 Mar;81:102388.
   PubMed Web of Science ®Google Scholar
• Fattizzo B, Cantoni S, Giannotta JA, et al. Efficacy and safety of cyclosporine a treatment in autoimmune cytopenias: the experience of two Italian reference centers. Ther Adv Hematol. 2022 May 14;13:20406207221097780. doi: 10.1177/20406207221097780
   Web of Science ®Google Scholar
• Berentsen S, Barcellini W, Longo DL. Autoimmune Hemolytic Anemias. N Engl J Med. 2021 Oct 7;385(15):1407–1419. doi: 10.1056/NEJMra2033982
   PubMed Web of Science ®Google Scholar
• Berentsen S. How I treat cold agglutinin disease. Blood. 2021 Mar 11;137(10):1295–1303. doi: 10.1182/blood.2019003809
   PubMed Web of Science ®Google Scholar
• Röth A, Hüttmann A, Rother RP, et al. Long-term efficacy of the complement inhibitor eculizumab in cold agglutinin disease. Blood. 2009 Apr 16; 113(16):3885–3886. doi: 10.1182/blood-2009-01-196329
   PubMed Web of Science ®Google Scholar
• Röth A, Bommer M, Hüttmann A, et al. Eculizumab in cold agglutinin disease (DECADE): an open-label, prospective, bicentric, nonrandomized phase 2 trial. Blood Adv. 2018 Oct 9; 2(19):2543–2549. doi: 10.1182/bloodadvances.2018024190
   PubMed Web of Science ®Google Scholar
• Ma K, Caplan S. Refractory IgG warm autoimmune hemolytic anemia treated with eculizumab: a novel application of anticomplement therapy. Case Rep Hematol. 2016;2016:9181698. doi: 10.1155/2016/9181698
   PubMedGoogle Scholar
• Roth A, Barcellini W, D’Sa S, et al. Complement C1s inhibition with sutimlimab results in durable response in cold agglutinin disease: CARDINAL study 1-year interim follow-up results. Haematologica. 2022 Jul 1; 107(7):1698–1702. doi: 10.3324/haematol.2021.279812
   PubMed Web of Science ®Google Scholar
• Röth A, Berentsen S, Barcellini W, et al. Sutimlimab in patients with cold agglutinin disease: results of the randomized placebo-controlled phase 3 CADENZA trial. Blood. 2022 Sep 1; 140(9):980–991. doi: 10.1182/blood.2021014955
   PubMed Web of Science ®Google Scholar
• Fattizzo B, Zaninoni A, Gianelli U, et al. Prognostic impact of bone marrow fibrosis and dyserythropoiesis in autoimmune hemolytic anemia. Am J Hematol. 2018 Aug;93(4):E88–E91. doi: 10.1002/ajh.25020
   PubMed Web of Science ®Google Scholar
• Fattizzo B, Pasquale R, Carpenedo M, et al. Bone marrow characteristics predict outcome in a multicenter cohort of primary immune thrombocytopenia patients treated with thrombopoietin analogs. Haematologica. 2019 Oct;104(10):e470–e473. doi: 10.3324/haematol.2019.216804
   PubMed Web of Science ®Google Scholar
• Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood. 1994 Jan 15;83(2):435–445. doi: 10.1182/blood.V83.2.435.435
   PubMed Web of Science ®Google Scholar
• Stasi R. Rituximab in autoimmune hematologic diseases: not just a matter of B cells. Semin Hematol. 2010 Apr;47(2):170–179. doi: 10.1053/j.seminhematol.2010.01.010
   PubMed Web of Science ®Google Scholar
• Motto DG, Williams JA, Boxer LA. Rituximab for refractory childhood autoimmune hemolytic anemia. Isr Med Assoc J. 2002 Nov;4(11):1006–1008.
   PubMed Web of Science ®Google Scholar
• Narat S, Gandla J, Hoffbrand AV, et al. Rituximab in the treatment of refractory autoimmune cytopenias in adults. Haematologica. 2005 Sep;90(9):1273–1274.
   PubMed Web of Science ®Google Scholar
• Bussone G, Ribeiro E, Dechartres A, et al. Efficacy and safety of rituximab in adults’ warm antibody autoimmune haemolytic anemia: retrospective analysis of 27 cases. Am J Hematol. 2009 Mar;84(3):153–157. doi: 10.1002/ajh.21341
   PubMed Web of Science ®Google Scholar
• Birgens H, Frederiksen H, Hasselbalch HC, et al. A phase III randomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia. Br J Haematol. 2013 Nov;163(3):393–399. doi: 10.1111/bjh.12541
   PubMed Web of Science ®Google Scholar
• Maung SW, Leahy M, O’Leary HM, et al. A multi-centre retrospective study of rituximab use in the treatment of relapsed or resistant warm autoimmune haemolytic anaemia. Br J Haematol. 2013 Oct;163(1):118–122. doi: 10.1111/bjh.12486
   PubMed Web of Science ®Google Scholar
• Michel M, Terriou L, Roudot-Thoraval F, et al. A randomized and double-blind controlled trial evaluating the safety and efficacy of rituximab for warm auto-immune hemolytic anemia in adults (the RAIHA study). Am J Hematol. 2017 Jan;92(1):23–27. doi: 10.1002/ajh.24570
   PubMed Web of Science ®Google Scholar
• Gutiérrez Jomarrón I, López Rubio M, Arias MM, et al. Autoimmune haemolytic anaemias: a retrospective study of 93 patients. Med Clin. 2020 May 8;154(9):331–337. English, Spanish. doi: 10.1016/j.medcli.2019.06.024
   PubMed Web of Science ®Google Scholar
• Berentsen S, Ulvestad E, Gjertsen BT, et al. Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients. Blood. 2004 Apr 15; 103(8):2925–2928. doi: 10.1182/blood-2003-10-3597
   PubMed Web of Science ®Google Scholar
• Schöllkopf C, Kjeldsen L, Bjerrum OW, et al. Rituximab in chronic cold agglutinin disease: a prospective study of 20 patients. Leuk Lymphoma. 2006 Feb;47(2):253–260. doi: 10.1080/10428190500286481
   PubMed Web of Science ®Google Scholar
• Berentsen S, Randen U, Vågan AM, et al. High response rate and durable remissions following fludarabine and rituximab combination therapy for chronic cold agglutinin disease. Blood. 2010 Oct 28; 116(17):3180–3184. doi: 10.1182/blood-2010-06-288647
   PubMed Web of Science ®Google Scholar
• Berentsen S, Randen U, Oksman M, et al. Bendamustine plus rituximab for chronic cold agglutinin disease: results of a Nordic prospective multicenter trial. Blood. 2017 Jul 27; 130(4):537–541. doi: 10.1182/blood-2017-04-778175
   PubMed Web of Science ®Google Scholar
• Berentsen S, Barcellini W, D’Sa S, et al. Cold agglutinin disease revisited: a multinational, observational study of 232 patients. Blood. 2020 Jul 23; 136(4):480–488. doi: 10.1182/blood.2020005674
   PubMed Web of Science ®Google Scholar
• Zaja F, Iacona I, Masolini P, et al. B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia. Haematologica. 2002 Feb;87(2):189–195. Erratum in: Haematologica 2002 Mar;87(3):336.
   PubMed Web of Science ®Google Scholar
• Zecca M, Nobili B, Ramenghi U, et al. Rituximab for the treatment of refractory autoimmune hemolytic anemia in children. Blood. 2003 May 15; 101(10):3857–3861. doi: 10.1182/blood-2002-11-3547
   PubMed Web of Science ®Google Scholar
• Dierickx D, Verhoef G, Van Hoof A, et al. Rituximab in auto-immune haemolytic anaemia and immune thrombocytopenic purpura: a Belgian retrospective multicentric study. J Intern Med. 2009 Nov;266(5):484–491. doi: 10.1111/j.1365-2796.2009.02126.x
   PubMedGoogle Scholar
• Peñalver FJ, Alvarez-Larrán A, Díez-Martin JL, et al. Multi-institutional retrospective study on the use of rituximab in refractory AIHA. Rituximab is an effective and safe therapeutic alternative in adults with refractory and severe autoimmune hemolytic anemia. Ann Hematol. 2010 Nov;89(11):1073–1080. doi: 10.1007/s00277-010-0997-y
   PubMed Web of Science ®Google Scholar
• Barcellini W, Zaja F, Zaninoni A, et al. Sustained response to low-dose rituximab in idiopathic autoimmune hemolytic anemia. Eur J Haematol. 2013 Dec;91(6):546–551. doi: 10.1111/ejh.12199
   PubMed Web of Science ®Google Scholar
• Ducassou S, Leverger G, Fernandes H, et al. Benefits of rituximab as a second-line treatment for autoimmune haemolytic anaemia in children: a prospective French cohort study. Br J Haematol. 2017 Jun;177(5):751–758. doi: 10.1111/bjh.14627
   PubMed Web of Science ®Google Scholar
• Chao SH, Chang YL, Yen JC, et al. Efficacy and safety of rituximab in autoimmune and microangiopathic hemolytic anemia: a systematic review and meta-analysis. Exp Hematol Oncol. 2020 Apr 15;9(1):6. doi: 10.1186/s40164-020-00163-5
   PubMed Web of Science ®Google Scholar
• Lee EJ, Kueck B. Rituxan in the treatment of cold agglutinin disease. Blood. 1998;92(9):3490–3491. doi: 10.1182/blood.V92.9.3490
   PubMed Web of Science ®Google Scholar
• A study of efficacy and safety of ianalumab in Previously treated patients with warm autoimmune hemolytic anemia (VAYHIA). ClinicalTrials.Gov Identifier: NCT05648968. [ Updated 2023 May 25; cited 2023 Jul 5]. Available from: https://classic.clinicaltrials.gov/ct2/show/NCT05648968
   Google Scholar
• Xu ZZ, Zhao BB, Xiong H, et al. Serum BAFF and APRIL levels in patients with autoimmune hemolytic anemia and their clinical significance. Int J Hematol. 2015 Oct;102(4):394–400. doi: 10.1007/s12185-015-1851-8
   PubMed Web of Science ®Google Scholar
• An open-label study of povetacicept in subjects with autoimmune cytopenias (RUBY-4). ClinicalTrials.Gov Identifier: NCT05757570. [ Updated 2023 Mar 7; cited 2023 Jul 5]. Available from: https://classic.clinicaltrials.gov/ct2/show/NCT05757570
   Google Scholar
• A study of obexelimab in patients with warm autoimmune hemolytic anemia (SApHiare). ClinicalTrials.Gov Identifier: NCT05786573. [ Updated 2023 May 19; cited 2023 Jul 5]. Available from: https://clinicaltrials.gov/study/NCT05786573
   Google Scholar
• Jalink M, Berentsen S, Castillo JJ, et al. Effect of ibrutinib treatment on hemolytic anemia and acrocyanosis in cold agglutinin disease/cold agglutinin syndrome. Blood. 2021 Nov 18; 138(20):2002–2005. doi: 10.1182/blood.2021012039
   PubMed Web of Science ®Google Scholar
• Ibrutinib in steroid refractory autoimmune hemolytic anemia (ISRAEL). ClinicalTrials.Gov Identifier: NCT03827603. [ Updated 2020 Jan 10; cited 2023 Jul 5]. Available from: https://classic.clinicaltrials.gov/ct2/show/NCT03827603
   Google Scholar
• Efficacy, safety and pharmacokinetics of Rilzabrutinib in patients with warm autoimmune hemolytic anemia (wAIHA). ClinicalTrials.Gov Identifier: NCT05002777. Updated 2023 May 31; cited 2023 Jul 5]. Available from: https://classic.clinicaltrials.gov/ct2/show/NCT05002777
   Google Scholar
• Kuter DJ, Rogers KA, Boxer MA, et al. Fostamatinib for the treatment of warm antibody autoimmune hemolytic anemia: phase 2, multicenter, open-label study. Am J Hematol. 2022 Jun 1; 97(6):691–699. doi: 10.1002/ajh.26508
   PubMed Web of Science ®Google Scholar
• Pasquale R, Giannotta JA, Barcellini W, et al. Bortezomib in autoimmune hemolytic anemia and beyond. Ther Adv Hematol. 2021 Nov 12;12:20406207211046428. doi: 10.1177/20406207211046428
   Web of Science ®Google Scholar
• Rossi G, Gramegna D, Paoloni F, et al. Short course of bortezomib in anemic patients with relapsed cold agglutinin disease: a phase 2 prospective GIMEMA study. Blood. 2018;132(5):547–550. doi: 10.1182/blood-2018-03-835413
   PubMed Web of Science ®Google Scholar
• Schuetz C, Hoenig M, Moshous D, et al. Daratumumab in life-threatening autoimmune hemolytic anemia following hematopoietic stem cell transplantation. Blood Adv. 2018 Oct 9; 2(19):2550–2553. doi: 10.1182/bloodadvances.2018020883
   PubMed Web of Science ®Google Scholar
• Cooling L, Hugan S. Daratumumab in combination with standard treatment for autoimmune hemolytic anemia in a pediatric patient. Transfusion. 2019 Dec;59(12):3801–3802. doi: 10.1111/trf.15539
   PubMedGoogle Scholar
• Blennerhassett R, Sudini L, Gottlieb D, et al. Post-allogeneic transplant Evans syndrome successfully treated with daratumumab. Br J Haematol. 2019 Oct;187(2):e48–e51. doi: 10.1111/bjh.16171
   PubMed Web of Science ®Google Scholar
• Even-Or E, Naser Eddin A, Shadur B, et al. Successful treatment with daratumumab for post-HSCT refractory hemolytic anemia. Pediatr Blood Cancer. 2020 Jan;67(1):e28010. doi: 10.1002/pbc.28010
   PubMed Web of Science ®Google Scholar
• Rieger MJ, Stolz SM, Ludwig S, et al. Daratumumab in rituximab-refractory autoimmune haemolytic anaemia. Br J Haematol. 2021 Sep;194(5):931–934. doi: 10.1111/bjh.17655
   PubMed Web of Science ®Google Scholar
• Jain A, Gupta DK. Daratumumab for refractory warm autoimmune hemolytic anemia. Ann Hematol. 2021 May;100(5):1351–1353. doi: 10.1007/s00277-020-04063-w
   PubMed Web of Science ®Google Scholar
• Tomkins O, Berentsen S, Arulogun S, et al. Daratumumab for disabling cold agglutinin disease refractory to B-cell directed therapy. Am J Hematol. 2020 Jul 11;95(10). doi: 10.1002/ajh.25932
   PubMed Web of Science ®Google Scholar
• Zaninoni A, Giannotta JA, Gallì A, et al. The immunomodulatory effect and clinical efficacy of daratumumab in a patient with cold agglutinin disease. Front Immunol. 2021 Mar 1;12:649441. doi: 10.3389/fimmu.2021.649441
   PubMed Web of Science ®Google Scholar
• Driouk L, Schmitt R, Peters A, et al. Daratumumab therapy for post-HSCT immune-mediated cytopenia: experiences from two pediatric cases and review of literature. Mol Cell Pediatr. 2021 Apr 29; 8(1):5. doi: 10.1186/s40348-021-00114-y
   PubMedGoogle Scholar
• Safety, pharmacokinetics, and efficacy of subcutaneous isatuximab in adults with warm autoimmune hemolytic anemia (wAIHA). ClinicalTrials.Gov Identifier: NCT04661033. [ Updated 2023 Mar 13; cited 2023 Jul 5]. Available from: https://classic.clinicaltrials.gov/ct2/show/NCT04661033
   Google Scholar
• Gupta N, Wang ES. Long-term response of refractory primary cold agglutinin disease to eculizumab therapy. Ann Hematol. 2014 Feb;93(2):343–344. doi: 10.1007/s00277-013-1800-7
   PubMed Web of Science ®Google Scholar
• Shapiro R, Chin-Yee I, Lam S. Eculizumab as a bridge to immunosuppressive therapy in severe cold agglutinin disease of anti-pr specificity. Clin Case Rep. 2015 Nov;3(11):942–944. doi: 10.1002/ccr3.399
   PubMedGoogle Scholar
• Makishima K, Obara N, Ishitsuka K, et al. High efficacy of eculizumab treatment for fulminant hemolytic anemia in primary cold agglutinin disease. Ann Hematol. 2019 Apr;98(4):1031–1032. doi: 10.1007/s00277-018-3521-4
   PubMed Web of Science ®Google Scholar
• Herbreteau L, Le Calloch R, Arnaud B, et al. Eculizumab, a real-life successful treatment for refractory cold agglutinin-mediated auto-immune hemolytic anemia secondary to lymphoproliferative disorders. Ann Hematol. 2021 Aug;100(8):2105–2106. doi: 10.1007/s00277-021-04557-1
   PubMed Web of Science ®Google Scholar
• Dawudi Y, Federici L, Debus J, et al. Cold agglutinin disease secondary to severe SARS-CoV-2 treated with eculizumab. BMJ Case Rep. 2022 Apr 29; 15(4):e242937. doi: 10.1136/bcr-2021-242937
   PubMedGoogle Scholar
• Chao MP, Hong J, Kunder C, et al. Refractory warm IgM-mediated autoimmune hemolytic anemia associated with Churg-Strauss syndrome responsive to eculizumab and rituximab. Am J Hematol. 2015 Jan;90(1):78–81. doi: 10.1002/ajh.23791
   PubMed Web of Science ®Google Scholar
• Neave L, Wilson AJ, Lissack M, et al. Severe refractory idiopathic warm autoimmune haemolytic anaemia responsive to complement inhibition with eculizumab. BMJ Case Rep. 2018 Dec 13; 11(1):e226429. doi: 10.1136/bcr-2018-226429
   PubMedGoogle Scholar
• Gauchy AC, Hentzien M, Wynckel A, et al. Efficacy of eculizumab in refractory life-threatening warm autoimmune hemolytic anemia associated with chronic myelomonocytic leukemia. Clin Case Rep. 2020 Aug 17;8(12):2641–2644. doi: 10.1002/ccr3.3250
   PubMed Web of Science ®Google Scholar
• Tahhan F, Huynh B, Xu P. Novel monoclonal antibody therapy in a patient with treatment-refractory warm autoimmune hemolytic anemia. Cureus. 2022 Jun 17;14(6):e26051. doi: 10.7759/cureus.26051
   PubMed Web of Science ®Google Scholar
• Jackson EM, Harper S, Webb GJ, et al. Severe refractory warm autoimmune haemolytic anaemia after the SARS-CoV-2 pfizer-BioNTech vaccine (BNT162b2 mRNA) managed with emergency splenectomy and complement inhibition with eculizumab. BMJ Case Rep. 2022 Aug 31; 15(8):e250774. doi: 10.1136/bcr-2022-250774
   PubMedGoogle Scholar
• Shi J, Rose EL, Singh A, et al. TNT003, an inhibitor of the serine protease C1s, prevents complement activation induced by cold agglutinins. Blood. 2014 Jun 26; 123(26):4015–4022. doi: 10.1182/blood-2014-02-556027
   PubMed Web of Science ®Google Scholar
• Jäger U, D’Sa S, Schörgenhofer C, et al. Inhibition of complement C1s improves severe hemolytic anemia in cold agglutinin disease: a first-in-human trial. Blood. 2019 Feb 28; 133(9):893–901. doi: 10.1182/blood-2018-06-856930
   PubMed Web of Science ®Google Scholar
• Röth A, Barcellini W, D’Sa S, et al. Sutimlimab in cold agglutinin disease. N Engl J Med. 2021 Apr 8;384(14):1323–1334. doi: 10.1056/NEJMoa2027760.
   PubMed Web of Science ®Google Scholar
• Tvedt THA, Steien E, Øvrebø B, et al. Sutimlimab, an investigational C1s inhibitor, effectively prevents exacerbation of hemolytic anemia in a patient with cold agglutinin disease undergoing major surgery. Am J Hematol. 2022 Feb 1;97(2):E51–E54. doi: 10.1002/ajh.26409
   PubMed Web of Science ®Google Scholar
• Röth A, Berentsen S, Barcellini W, et al. Sustained efficacy of sutimlimab, a complement c1s inhibitor, in patients with cold agglutinin disease: results from part b of the phase 3 cadenza study. Poster presented at EHA, Frankfurt, 2023
   Google Scholar
• Röth A, Barcellini W, Tvedt THA, et al. Sutimlimab improves quality of life in patients with cold agglutinin disease: results of patient-reported outcomes from the CARDINAL study. Ann Hematol. 2022 Oct;101(10):2169–2177. doi: 10.1007/s00277-022-04948-y
   PubMed Web of Science ®Google Scholar
• Gertz M, Roman E, Fattizzo B, et al. Inhibition of C3 with APL-2 controls haemolysis and increases haemoglobin levels in subjects with autoimmune haemolytic anaemia (AIHA). EHA Lib. 2019;3:S899. doi: 10.1097/01.HS9.0000561876.96057.48
   Google Scholar
• A study to evaluate the efficacy and safety of pegcetacoplan in patients with cold agglutinin disease (CAD). ClinicalTrials.Gov Identifier: NCT05096403. [ Updated 2023 Jun 2; cited 2023 Jul 5]. Available from: https://classic.clinicaltrials.gov/ct2/show/NCT05096403
   Google Scholar
• Basket study to assess efficacy, safety and PK of iptacopan (LNP023) in autoimmune benign hematological disorders. ClinicalTrials.Gov Identifier: NCT05086744. [ Updated 2023 Jul 3; cited 2023 Jul 5]. Available from: https://classic.clinicaltrials.gov/ct2/show/NCT05086744
   Google Scholar
• Barcellini W, Zaninoni A, Giannotta JA, et al. New insights in autoimmune hemolytic anemia: from pathogenesis to therapy stage 1. J Clin Med. 2020 Nov 27;9(12):3859. doi: 10.3390/jcm9123859
   PubMed Web of Science ®Google Scholar
• Garg M, Agarwal S, Altohami M. A single dose of eculizumab terminated life-threatening haemolysis in idiopathic IgM-mediated warm autoimmune haemolytic anaemia: a case report. Br J Haematol. 2022 Apr;197(2):e28–e31. doi: 10.1111/bjh.18011
   PubMed Web of Science ®Google Scholar
• Study to assess the safety, tolerability, efficacy and PK of APL-2 in patients with warm type autoimmune hemolytic anemia (wAIHA) or cold agglutinin disease (CAD). ClinicalTrials.Gov Identifier: NCT03226678. [ Updated 2023 Apr 3; cited 2023 Jul 5]. Available from: https://classic.clinicaltrials.gov/ct2/show/NCT03226678
   Google Scholar
• Safety, tolerability, pharmacokinetics and pharmacodynamics of ANX005 in participants with warm autoimmune hemolytic anemia (wAIHA). ClinicalTrials.Gov Identifier: NCT04691570. [ Updated 2023 Mar 6; cited 2023 Jul 5]. Available from: https://classic.clinicaltrials.gov/ct2/show/NCT04691570
   Google Scholar
• A safety study of SYNT001 in participants with warm autoimmune hemolytic anemia (WAIHA). ClinicalTrials.Gov Identifier: NCT03075878. [ Updated 2020 May 13; cited 2023 Jul 5]. Available from: https://classic.clinicaltrials.gov/ct2/show/NCT03075878
   Google Scholar
• To assess the efficacy and safety of RVT-1401 in the treatment of warm autoimmune hemolytic anemia (ASCEND-WAIHA). ClinicalTrials.Gov Identifier: NCT04253236. [ Updated 2022 Jul 28; cited 2023 Jul 5]. Available from: https://classic.clinicaltrials.gov/ct2/show/NCT04253236
   Google Scholar